GH · Guardant Health, Inc. · Earnings Call Transcripts & Audio
Market Cap
$24.57B
Shares
134.20M
Guardant Health, Inc. Earnings Call Transcripts
Quarterly earnings calls for Guardant Health, Inc. (GH), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲23.9%
$117.40M
−$161.99M
'22 Q3
22-11-03
▲17.4%
$126.89M
−$139.93M
'22 Q4
23-02-23
▲33.9%
$128.71M
−$133.53M
'23 Q1
23-05-09
▲25.7%
$137.15M
−$72.77M
'23 Q2
23-08-03
▲21.8%
$143.03M
−$86.10M
'23 Q3
23-11-06
▲22.2%
$155.05M
−$187.04M
'23 Q4
24-02-22
▲30.9%
$168.49M
−$114.98M
'24 Q1
24-05-09
▲29.2%
$177.24M
−$102.63M
'24 Q2
24-08-07
▲33.9%
$191.48M
−$107.75M
'24 Q3
24-11-06
▲30.2%
$201.81M
−$111.01M
'24 Q4
25-02-20
▲20.8%
$203.47M
−$95.16M
'25 Q1
25-04-30
▲30.9%
$232.09M
−$99.90M
'25 Q2
25-07-30
▲38.5%
$265.20M
−$92.72M
'25 Q3
25-10-29
▲39.4%
$281.27M
−$128.49M
'25 Q4
26-02-19
▲48.3%
$301.67M
−$112.08M
'26 Q1
26-05-07
LATEST
▲44.3%
$334.98M
−$120.14M
'26 Q2
26-07-30
Conference
Investor event
2026-09-15
Guardant Health, Inc. (GH) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-08-12
Guardant Health, Inc. (GH) August 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-07-30
Guardant Health, Inc. (GH) Q2 2026 Earnings Call Transcript
Confident tone
SHIELD colorectal cancer screening momentum
Reveal MRD growth and pipeline
Oncology business volume and revenue
Revenue
$334.98M
▲ 44.3% YoY Diluted EPS
$-0.90
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-03
Guardant Health, Inc. (GH) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-02
Guardant Health, Inc. (GH) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-07
Guardant Health, Inc. (GH) Q1 2026 Earnings Call Transcript
Confident tone
Screening (Shield) business
Oncology business performance
Reveal MRD product
Revenue
$301.67M
▲ 48.3% YoY Diluted EPS
$-0.85
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-03-11
Guardant Health, Inc. (GH) March 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-19
Guardant Health, Inc. (GH) Q4 2025 Earnings Call Transcript
Confident tone
Shield Screening and Multi-Cancer Detection
MRD and Reveal Product Expansion
Oncology Business and Guardant360 Smart Platform
Revenue
$281.27M*
▲ 39.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-29
Guardant Health, Inc. (GH) Q3 2025 Earnings Call Transcript
Confident tone
Screening / Shield launch
Competition in colorectal cancer screening
Reveal / MRD progress
Revenue
$265.20M
▲ 38.5% YoY Diluted EPS
$-0.74
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-30
Guardant Health, Inc. (GH) Q2 2025 Earnings Call Transcript
Confident tone
Oncology volume and revenue growth
Shield CRC screening commercialization
Reveal MRD progress and reimbursement
Revenue
$232.09M
▲ 30.9% YoY Diluted EPS
$-0.80
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-04-30
Guardant Health, Inc. (GH) Q1 2025 Earnings Call Transcript
Confident tone
Oncology business performance
Shield CRC screening
Reveal MRD progress and reimbursement
Revenue
$203.47M
▲ 20.8% YoY Diluted EPS
$-0.77
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-20
Guardant Health, Inc. (GH) Q4 2024 Earnings Call Transcript
Confident tone
Therapy Selection Growth and Guardant360 Upgrade
Reveal MRD and CRC Surveillance Coverage
Clinical Evidence and Guidelines
Revenue
$201.81M*
▲ 30.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Guardant Health, Inc. (GH) Q3 2024 Earnings Call Transcript
Confident tone
Precision Oncology / Guardant360 LVT Upgrade
Shield CRC Screening Launch and Reimbursement
Reimbursement and Pricing Tailwinds
Revenue
$191.48M
▲ 33.9% YoY Diluted EPS
$-0.88
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Guardant Health, Inc. (GH) Q2 2024 Earnings Call Transcript
Confident tone
FDA Approval of Shield for CRC Screening
Clinical Volume Growth (G360 and Beyond)
Shield Commercial Launch and Market Opportunity
Revenue
$177.24M
▲ 29.2% YoY Diluted EPS
$-0.84
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Guardant Health, Inc. (GH) Q1 2024 Earnings Call Transcript
Balanced tone
Interest rate environment and rate sensitivity
Capital recycling and distribution policy
Investment pipeline and new construction LIHTC challenges
Revenue
$168.49M
▲ 30.9% YoY Diluted EPS
$-0.94
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-22
Guardant Health, Inc. (GH) Q4 2023 Earnings Call Transcript
Positive tone
Therapy Selection growth and reimbursement
MRD / Reveal platform
Shield CRC screening / FDA
Revenue
$155.05M*
▲ 22.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-06
Guardant Health, Inc. (GH) Q3 2023 Earnings Call Transcript
Revenue
$143.03M
▲ 21.8% YoY Diluted EPS
$-0.73
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Guardant Health, Inc. (GH) Q2 2023 Earnings Call Transcript
Revenue
$137.15M
▲ 25.7% YoY Diluted EPS
$-0.67
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Guardant Health, Inc. (GH) Q1 2023 Earnings Call Transcript
Revenue
$128.71M
▲ 33.9% YoY Diluted EPS
$-1.30
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-23
Guardant Health, Inc. (GH) Q4 2022 Earnings Call Transcript
Revenue
$126.89M*
▲ 17.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Guardant Health, Inc. (GH) Q3 2022 Earnings Call Transcript
Revenue
$117.40M
▲ 23.9% YoY Diluted EPS
$-1.58
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Guardant Health, Inc. (GH) Q2 2022 Earnings Call Transcript
Revenue
$109.14M
▲ 18.5% YoY Diluted EPS
$-2.25
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Guardant Health, Inc. (GH) Q1 2022 Earnings Call Transcript
Revenue
$96.10M
▲ 22.2% YoY Diluted EPS
$-1.21
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-23
Guardant Health, Inc. (GH) Q4 2021 Earnings Call Transcript
Revenue
$108.11M*
▲ 38% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Guardant Health, Inc. (GH) Q3 2021 Earnings Call Transcript
Revenue
$94.78M
▲ 27.1% YoY Diluted EPS
$-1.06
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Guardant Health, Inc. (GH) Q2 2021 Earnings Call Transcript
Revenue
$92.10M
▲ 38.8% YoY Diluted EPS
$-0.96
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Guardant Health, Inc. (GH) Q1 2021 Earnings Call Transcript
Revenue
$78.67M
▲ 16.5% YoY Diluted EPS
$-1.09
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-24
Guardant Health, Inc. (GH) Q4 2020 Earnings Call Transcript
Revenue
$78.32M*
▲ 24.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Guardant Health, Inc. (GH) Q3 2020 Earnings Call Transcript
Revenue
$74.57M
▲ 22.5% YoY Diluted EPS
$-0.78
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Guardant Health, Inc. (GH) Q2 2020 Earnings Call Transcript
Revenue
$66.33M
▲ 22.9% YoY Diluted EPS
$-0.57
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Guardant Health, Inc. (GH) Q1 2020 Earnings Call Transcript
Revenue
$67.51M
▲ 84.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-24
Guardant Health, Inc. (GH) Q4 2019 Earnings Call
Revenue
$62.90M*
▲ 91.3% YoY
Rev · 7q
Audio
Transcript
Slides
8-K10-K
Showing 1–32 of 32 earnings calls
Key facts
CIK
1576280
CUSIP
40131M109
13F (30d)
15 filings
14 filers
Visit website
Investor relations